Treatment of invasive male breast cancer: a 40-year single-institution experience

被引:3
作者
Meattini, I. [1 ]
Livi, L. [1 ]
Franceschini, D. [1 ]
Saieva, C. [2 ]
Scotti, V. [1 ]
Casella, D. [3 ]
Criscenti, V. [3 ]
Zanna, I. [2 ]
Meacci, F. [1 ]
Gerlain, E. [2 ]
Agresti, B. [1 ]
Mangoni, M. [1 ]
Paiar, F. [1 ]
Simontacchi, G. [1 ]
Greto, D. [1 ]
Nori, J. [4 ]
Bianchi, S. [5 ]
Cataliotti, L. [3 ]
Biti, G. [1 ]
机构
[1] Univ Florence, Radiotherapy Unit, Dept Med & Surg Crit Care, I-50134 Florence, Italy
[2] Univ Florence, ISPO Canc Res & Prevent Inst, Mol & Nutr Epidemiol Unit, I-50134 Florence, Italy
[3] Univ Florence, Dept Med & Surg Crit Care, Dept Surg, I-50134 Florence, Italy
[4] Univ Florence, Dept Med & Surg Crit Care, Diagnost Senol Unit, I-50134 Florence, Italy
[5] Univ Florence, Div Anat Pathol, Dept Med & Surg Crit Care, I-50134 Florence, Italy
来源
RADIOLOGIA MEDICA | 2013年 / 118卷 / 03期
关键词
Male breast cancer; Prognostic factors; Surgery; Mastectomy; Breast-conserving surgery; Radiotherapy; LYMPH-NODE BIOPSY; CARCINOMA; MEN; MANAGEMENT; MUTATIONS;
D O I
10.1007/s11547-012-0867-x
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
We conducted a retrospective analysis to evaluate the management and outcome of invasive male breast cancer treated in a single-institution over a period of 40 years. We reviewed the clinical and pathological features of 60 male patients affected by breast carcinoma treated at our Radiotherapy Unit between 1971 and 2011. Tumours were classified according to histological type and the updated 2010 TNM classification of malignant tumours. At a median follow-up of 8.9 [range, 0.6-20; standard deviation (SD), 4.98] years, 32 patients (53.3%) were alive and 16 patients died (26.7%) due to disease progression and 12 (20%) due to other causes. At univariate analysis for overall survival, pathological tumour size (p=0.031), histological subtype (p=0.013) and nodal status (p=0.006) emerged as significant predictors of death. At multivariate analysis, independent death predictors were advanced pathological tumour size (p=0.016), positive nodal status (p=0.003) and invasive cribriform histological type (p=0.0003). In consideration of the rarity of the disease, many issues are still being debated, and future collaborative studies are required. However, our experience confirms the prognostic role of greater pathological tumour size and positive nodal status as unfavourable features for survival in male breast cancer.
引用
收藏
页码:476 / 486
页数:11
相关论文
共 37 条
[1]   Is male breast cancer similar or different than female breast cancer? [J].
Anderson, WF ;
Althuis, MD ;
Brinton, LA ;
Devesa, SS .
BREAST CANCER RESEARCH AND TREATMENT, 2004, 83 (01) :77-86
[2]  
ANELLI A, 1995, CANCER, V75, P2233, DOI 10.1002/1097-0142(19950501)75:9<2233::AID-CNCR2820750907>3.0.CO
[3]  
2-S
[4]  
[Anonymous], 2011, TNM CLASSIFICATION M
[5]   CURRENT MANAGEMENT OF MALE BREAST-CANCER - A REVIEW OF 104 CASES [J].
BORGEN, PI ;
WONG, GY ;
VLAMIS, V ;
POTTER, C ;
HOFFMANN, B ;
KINNE, DW ;
OSBORNE, MP ;
MCKINNON, WMP .
ANNALS OF SURGERY, 1992, 215 (05) :451-459
[6]   KI67 IMMUNOSTAINING IN PRIMARY BREAST-CANCER - PATHOLOGICAL AND CLINICAL ASSOCIATIONS [J].
BOUZUBAR, N ;
WALKER, KJ ;
GRIFFITHS, K ;
ELLIS, IO ;
ELSTON, CW ;
ROBERTSON, JFR ;
BLAMEY, RW ;
NICHOLSON, RI .
BRITISH JOURNAL OF CANCER, 1989, 59 (06) :943-947
[7]  
Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365
[8]   Efficacy of sentinel lymph node biopsy in male breast cancer [J].
Cimmino, VM ;
Degnim, AC ;
Sabel, MS ;
Diehl, KM ;
Newman, LA ;
Chang, AE .
JOURNAL OF SURGICAL ONCOLOGY, 2004, 86 (02) :74-77
[9]   Male breast cancer: Results of the treatments and prognostic factors in 397 cases [J].
Cutuli, B ;
Lacroze, M ;
Dilhuydy, JM ;
Velten, M ;
DeLafontan, B ;
Marchal, C ;
Resbeut, M ;
Graic, Y ;
Campana, F ;
MonchoBernier, V ;
DeGislain, C ;
Tortochaux, J ;
Cuillere, JC ;
RemeSaumon, M ;
NGuyen, TD ;
Lesaunier, F ;
LeSimple, T ;
Gamelin, E ;
Hery, M ;
Berlie, J .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (12) :1960-1964
[10]   Strategies in treating male breast cancer [J].
Cutuli, Bruno .
EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (02) :193-202